B0F Stock Chart & Stats
€5.06
-€0.14(-2.24%)
At close: 4:00 PM EST
€5.06
-€0.14(-2.24%)
Day’s Range― - ―
52-Week Range€3.97 - €7.46
Previous CloseN/A
Volume527.00
Average Volume (3M)152.00
Market Cap
€98.41M
Enterprise Value€1.08B
Total Cash (Recent Filing)€106.09M
Total Debt (Recent Filing)€4.58M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 21, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding23,273,417
10 Day Avg. Volume300
30 Day Avg. Volume152
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€37.35M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthHistorical top-line expansion has been consistent: revenue scaled meaningfully over several years and remains positive in the trailing twelve months. Durable demand for the therapy suggests continued installations and utilization can drive multi-period revenue resilience independent of near-term profit swings.
Low Leverage / Conservatively Financed Balance SheetA very low debt burden provides long-term financial flexibility, lowering refinancing and solvency risk. With minimal leverage the company can fund growth, absorb temporary operating losses, and invest in commercialization or R&D without immediate pressure to cut strategic programs or raise costly external capital.
Recurring Revenue And Distribution ModelA business model blending capital placements with recurring consumables and service creates durable, annuity-like revenue from installed systems. International distribution partnerships expand reach while keeping CAPEX light for some markets, supporting predictable revenue streams as installed base grows.
Bears Say
Profitability Deterioration Into LossesThe company moved from healthy profits in 2023–2024 to net losses in 2025 and the trailing twelve months. Persistent negative net income undermines reinvestment capacity, raises break-even risk, and could force strategic trade-offs if margins do not recover over the medium term.
Weak And Negative Cash GenerationOperating cash flow and free cash flow swung negative, reversing prior strong cash generation. Sustained negative cash flow strains liquidity, can limit organic funding for sales or installs, and increases reliance on external funding if losses persist, elevating execution risk over the next several quarters.
Negative Returns On EquityROE turning negative indicates the company is not generating returns from its equity base, signaling capital inefficiency. Over 2–6 months this can pressure capital allocation choices and investor confidence, and suggests management must materially improve profitability or risk suboptimal use of balance-sheet resources.
Paxman AB News
B0F FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was €3.97 and its highest was €7.46 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is €98.41M.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is Aug 21, 2026 which is in 27 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on May 21, 2026. The company reported €0 earnings per share for the quarter, missing the consensus estimate of €0.009 by -€0.009.
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.04.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of €0 in its last earnings report, missing expectations of €0.009. Following the earnings report the stock price went up 3.44%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in DE:B0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
B0F Earnings Call
Q1 2026
0:00 / 0:00